Lung cancer is not a single disease. The term covers a group of distinct cancer types that originate in different cell populations within the lung, grow at different rates, spread through different pathways, and respond to very different treatments. Understanding which type of lung cancer is present is not a secondary detail in the diagnostic process; it is the foundational step that determines everything that follows, from the treatment options available to the likely clinical course and the monitoring strategy needed over time.
For patients and families navigating a lung cancer diagnosis, knowing the specific type matters enormously and shapes the decisions made at every stage of care. In this article, we will explain the main types of lung cancer clearly and in practical terms, how each type behaves and where it typically arises within the lung, which risk factors are most associated with each subtype, how they are diagnosed and staged, what treatment approaches are used for each, and why the type of lung cancer directly influences the role of imaging in diagnosis and monitoring.
The Two Main Categories of Lung Cancer
All lung cancers are divided at the highest level into two broad categories based on how the cancer cells appear under a microscope: non-small cell lung cancer and small cell lung cancer. This distinction is not merely academic. The two categories behave so differently in terms of growth rate, spread patterns, and treatment response that they are essentially managed as entirely separate diseases despite sharing the same organ of origin.
Non-small cell lung cancer accounts for approximately 85 percent of all lung cancers and is itself a group of distinct subtypes with their own biological characteristics and clinical behaviors. Small cell lung cancer accounts for the remaining 15 percent and is one of the most aggressive malignancies in oncology, characterized by rapid growth and early widespread dissemination. The distinction between these two categories is established through pathological examination of biopsy tissue and is the first and most important result a patient awaits after a lung tissue sample is obtained. Accurate staging following this distinction requires comprehensive imaging, and the CT scan is the cornerstone imaging tool used for both categories at the time of diagnosis and throughout treatment. Our full lung cancer overview covers the broader context of the disease including causes, risk factors, and treatment pathways beyond what the type-specific discussion below addresses.
Non-Small Cell Lung Cancer: The Three Main Subtypes
Adenocarcinoma
Adenocarcinoma is the most common type of lung cancer overall, accounting for approximately 40 percent of all cases. It arises from the mucus-producing glandular cells lining the small airways and alveoli in the peripheral lung tissue, which means it typically develops away from the central bronchi in the outer zones of the lung. This peripheral location is one reason adenocarcinoma tends to produce fewer early symptoms than central tumors; it can grow to a meaningful size without causing airway obstruction or hemoptysis.
Adenocarcinoma is the most common subtype in non-smokers and in women, and it is the subtype most frequently associated with targetable molecular mutations including EGFR, ALK, ROS1, BRAF, MET, and RET alterations. This molecular landscape makes adenocarcinoma the subtype most amenable to precision-targeted therapy, and comprehensive molecular testing of biopsy tissue is now standard practice for all advanced adenocarcinoma patients. Molecular profiling of lung adenocarcinoma directly determines which targeted agents are applicable, making the quality and adequacy of the initial biopsy critically important to subsequent treatment decisions.
On imaging, lung adenocarcinoma often presents as a peripheral nodule or mass that may have irregular or spiculated margins, suggesting malignant growth characteristics. In situ adenocarcinoma, previously known as bronchioloalveolar carcinoma, appears as ground-glass opacity on CT rather than a solid nodule, and may be multifocal. The CT scan of the chest is the primary imaging tool for characterizing adenocarcinoma lesions, assessing their relationship to the pleura and fissures, and evaluating lymph node involvement in preparation for treatment planning. Follow-up CT is essential throughout treatment to monitor response, particularly for patients receiving targeted therapies where imaging is the primary tool for assessing whether the tumor is shrinking or developing resistance.
Squamous Cell Carcinoma
Squamous cell carcinoma accounts for approximately 25 to 30 percent of non-small cell lung cancers and arises from the flat cells lining the central airways, typically the main or lobar bronchi. Its central origin is a defining characteristic that shapes its clinical behavior: because it develops near the major breathing tubes, it more commonly causes symptoms related to airway obstruction, including cough, hemoptysis, and recurrent pneumonia in the obstructed lung segment, earlier in its course than peripheral tumors.
Squamous cell carcinoma is very strongly associated with tobacco smoking and is relatively uncommon in never-smokers. It tends to grow more slowly than adenocarcinoma and small cell lung cancer, and it less commonly spreads to the brain compared to the other major lung cancer types. However, when centrally located, it can cause significant local complications including obstruction of major airways, invasion of the mediastinum, and involvement of major blood vessels.
Molecularly, squamous cell carcinoma less commonly harbors the driver mutations that respond to current targeted therapies compared to adenocarcinoma, though research continues to identify actionable targets in this subtype. PD-L1 expression testing is performed at diagnosis to assess suitability for immunotherapy, which has become an important treatment option for squamous cell carcinoma at both early and advanced stages. CT imaging characteristically shows a central mass, sometimes with associated cavitation or post-obstructive consolidation in the downstream lung, and the full imaging services at Images support the workup and monitoring of squamous cell carcinoma cases in Kuwait.
Large Cell Carcinoma
Large cell carcinoma accounts for approximately 10 to 15 percent of non-small cell lung cancers and is defined by exclusion: it is a lung cancer that does not have the microscopic features of adenocarcinoma, squamous cell carcinoma, or small cell carcinoma. It is sometimes referred to as undifferentiated large cell carcinoma, reflecting the absence of specific differentiation markers on pathological analysis. Large cell carcinomas can arise anywhere in the lung, tend to be fast-growing, and may present as large peripheral masses at the time of diagnosis.
A specific variant called large cell neuroendocrine carcinoma has biological behavior that is closer to small cell lung cancer than to conventional non-small cell subtypes, with a particularly aggressive course and poor prognosis. This variant is treated more like small cell lung cancer in terms of systemic therapy approach. Large cell carcinoma requires the same comprehensive pathological and molecular workup as other non-small cell subtypes, and the same imaging pathway applies for staging and monitoring. The MRI of the brain is included in staging workup for large cell carcinoma given its aggressive behavior, as intracranial metastases are a concern in rapidly growing lung cancers of any subtype.
Small Cell Lung Cancer
Small cell lung cancer is a category apart from non-small cell subtypes in almost every clinically meaningful way. It arises from neuroendocrine cells in the bronchial epithelium and is characterized by rapid cell division, early and widespread lymphatic and hematogenous spread, and high sensitivity to initial chemotherapy. It is so strongly associated with tobacco smoking that small cell lung cancer in a non-smoker is considered a diagnostic rarity that warrants additional investigation to confirm the diagnosis.
Small cell lung cancer is staged using a simplified two-stage system rather than the TNM system used for non-small cell lung cancer. Limited stage means the disease is confined to one hemithorax and can be encompassed within a radiation treatment field. Extensive stage means the disease has spread beyond one hemithorax or to distant organs. The majority of patients, approximately 60 to 70 percent, present with extensive stage disease at diagnosis because of the cancer’s aggressive growth and early dissemination.
Small cell lung cancer staging requires comprehensive imaging including CT of the chest and abdomen and, critically, MRI of the brain. Brain metastases are present at diagnosis in a significant proportion of extensive stage patients, and even in limited stage disease, prophylactic cranial irradiation is considered because of the high risk of subsequent brain involvement. The brain MRI service at Images, using 3 Tesla technology, provides the high-resolution imaging sensitivity needed to detect small brain metastases in lung cancer staging, and is available at all three Kuwait branches for patients requiring this assessment as part of their workup.
Despite its initial sensitivity to chemotherapy, small cell lung cancer has a high rate of relapse after first-line treatment, and relapsed disease is often resistant to further therapy. Second-line options exist but generally produce responses that are less durable than first-line treatment. The addition of immunotherapy to first-line chemotherapy for extensive stage disease has modestly extended survival in recent trials and is now part of standard care in many settings. The role of imaging in monitoring small cell lung cancer throughout treatment is substantial, and the CT scan is used at regular intervals to assess response and detect disease progression.
Less Common Lung Cancer Types
Carcinoid Tumors
Carcinoid tumors of the lung are a rare type of neuroendocrine tumor that account for approximately one to two percent of lung cancers. They are classified as typical or atypical carcinoids based on their mitotic rate and the presence or absence of necrosis on pathological examination. Typical carcinoids behave in a relatively indolent fashion, grow slowly, and are associated with excellent long-term outcomes after surgical resection. Atypical carcinoids are more aggressive, with a higher rate of lymph node involvement and distant metastasis.
Carcinoid tumors most commonly arise in the central airways and may present with symptoms of airway obstruction, hemoptysis, or, less commonly, carcinoid syndrome when they produce hormones that reach the systemic circulation in sufficient quantities. On CT imaging, they often appear as well-defined central or peripheral nodules, sometimes with calcification. Surgical resection is the primary treatment for localized carcinoids, and these tumors are generally managed very differently from the aggressive lung cancer types described above. Understanding how distinct each lung cancer subtype is from the others highlights why accurate pathological diagnosis is so essential before any treatment plan is finalized.
Mesothelioma
Mesothelioma is sometimes grouped with lung cancers in discussion but is technically a distinct entity. It arises from the mesothelial cells lining the pleura, the membrane surrounding the lung, rather than from the lung tissue itself. It is almost exclusively associated with asbestos exposure and has a long latency period of twenty to fifty years between exposure and clinical presentation. Pleural mesothelioma presents with breathlessness due to pleural effusion, chest pain, and constitutional symptoms, and is often diagnosed at an advanced stage due to its initially non-specific presentation.
CT imaging typically shows pleural thickening, pleural effusion, and in advanced cases encasement of the lung by pleural tumor. MRI of the chest provides additional detail for assessing chest wall invasion, diaphragmatic involvement, and mediastinal extension in patients being considered for surgical approaches. While technically not a primary lung cancer, mesothelioma is managed within the thoracic oncology team and requires the same comprehensive imaging workup for staging and treatment planning. Patients in Kuwait with suspected pleural disease can access chest CT and MRI at Images Diagnostic Center as part of their diagnostic evaluation.
How Lung Cancer Type Affects Diagnosis and Imaging
The type of lung cancer significantly influences how the diagnostic and staging imaging pathway is structured. For all lung cancer types, CT of the chest is the foundational imaging study that characterizes the primary tumor and evaluates regional lymph nodes and adjacent structures. However, the extent of staging imaging beyond the chest varies by type and stage.
For non-small cell lung cancer, CT of the abdomen and pelvis is added to assess for distant metastases in the liver, adrenal glands, and other abdominal organs. MRI of the brain is added in stage III and IV disease or when neurological symptoms are present. For small cell lung cancer, brain MRI is performed at diagnosis for all patients regardless of stage or symptoms, given the high prevalence of occult brain metastases. The choice between Open MRI and standard MRI at Images can be guided by patient comfort needs, and both options are available to ensure that no patient is unable to access the brain imaging they need due to claustrophobia or scan-related anxiety.
For patients in Kuwait being assessed for lung cancer, having access to both CT and high-field MRI at the same imaging provider simplifies the coordination of a comprehensive staging workup. The imaging services at Images cover both CT and MRI across all three branches, allowing patients to complete multiple components of their staging imaging at a single, familiar provider without logistical complexity. For patients also wanting to understand more about how the specific symptoms they experienced led to their diagnosis, our dedicated article on lung cancer symptoms provides a thorough breakdown of the warning signs associated with different tumor locations and stages.
How Lung Cancer Type Guides Treatment
Treatment for lung cancer is entirely shaped by its type, subtype, and molecular profile. This is why the pathological diagnosis, including subtype determination and molecular testing, is as important as any imaging finding in the overall management plan. Two patients with stage III lung cancer can have completely different treatment plans if one has EGFR-mutant adenocarcinoma and the other has squamous cell carcinoma with high PD-L1 expression.
Adenocarcinoma with a targetable mutation receives a specific oral targeted therapy matched to that mutation, often as monotherapy without chemotherapy. Squamous cell carcinoma without a targetable mutation may receive chemotherapy combined with immunotherapy. Small cell lung cancer receives platinum-based chemotherapy with or without immunotherapy and concurrent radiation for limited stage disease. Large cell neuroendocrine carcinoma is treated similarly to small cell. Carcinoid tumors are managed with surgery as the primary approach. Each of these treatment paths produces different imaging-based response patterns, and the imaging monitoring strategy throughout treatment is adapted accordingly.
For patients receiving treatment for any lung cancer subtype in Kuwait, regular CT and where relevant MRI monitoring is a core part of their care. The CT scan service at Images is accessible across three Kuwait branches and is used to support the clinical teams managing lung cancer patients through the sequential imaging assessments that treatment monitoring requires. For patients interested in understanding how CT fits into cancer care more broadly, our article on CT scan uses provides context on the range of clinical situations where this modality is the tool of choice.
Frequently Asked Questions
Which type of lung cancer is most common?
Adenocarcinoma is the most common type of lung cancer globally, accounting for approximately 40 percent of cases. It is the most frequent subtype in non-smokers and in women, and is characterized by specific molecular mutations that make it the most amenable to targeted therapy. Squamous cell carcinoma is the second most common type, followed by large cell carcinoma. Small cell lung cancer accounts for approximately 15 percent of cases overall.
Is small cell lung cancer more serious than non-small cell?
Small cell lung cancer is generally considered more aggressive than most non-small cell subtypes because it grows rapidly, spreads early, and is diagnosed at an advanced stage in the majority of patients. While it is initially very sensitive to chemotherapy, it commonly relapses and is more difficult to treat at relapse. Non-small cell lung cancer, particularly early-stage adenocarcinoma or squamous cell carcinoma, can be cured with surgery. Small cell lung cancer has a more limited rate of long-term cure, though limited stage disease treated with combined chemoradiotherapy does achieve durable remission in some patients.
Can lung cancer type change over time?
The primary cancer type does not change, but tumors can transform or develop new characteristics under treatment pressure. A notable example is transformation of EGFR-mutant adenocarcinoma to small cell-like cancer as a mechanism of resistance to EGFR targeted therapy. This phenomenon, though relatively uncommon, is clinically important because it requires a change in treatment approach. Repeat biopsy at the time of progression is sometimes performed to assess for resistance mechanisms including this type of histological transformation, alongside imaging reassessment with CT.
Does the type of lung cancer affect which imaging is needed?
Yes, significantly. Brain MRI is performed at diagnosis in all small cell lung cancer patients and in advanced non-small cell patients because of the high risk of intracranial spread. For adenocarcinoma with a targetable mutation, treatment response imaging focuses on the primary site and known metastases. For squamous cell carcinoma, CT monitoring tracks lymph node and pulmonary response. The specific imaging protocol is adapted to the tumor type, stage, and treatment received, and the imaging team at Images supports each of these requirements across its Kuwait branches.
Why is molecular testing important in lung cancer?
Molecular testing identifies specific genetic alterations in the cancer cells that determine which targeted therapies are effective. Without this information, patients with targetable mutations may be treated with standard chemotherapy when a more effective oral targeted agent is available. Conversely, patients without targetable mutations avoid ineffective targeted drugs. Molecular testing has fundamentally changed outcomes for a significant proportion of adenocarcinoma patients and is now considered a standard requirement in the diagnostic workup of advanced non-small cell lung cancer worldwide.
Is lung cancer type determined before or after staging imaging?
Pathological determination of lung cancer type is made from biopsy tissue, which is typically obtained after the primary lesion is identified on imaging. Staging imaging, which assesses disease extent, proceeds simultaneously or immediately after tissue sampling. In practice, the type is often determined around the same time as or shortly after staging imaging is completed, as the full clinical picture including both pathological and staging information is needed to finalize the treatment plan. Timely access to CT and MRI imaging at Images helps minimize the delay between tissue diagnosis and the completion of staging in Kuwait-based patients.
Understanding Your Diagnosis and Your Next Step
Knowing the type of lung cancer is the foundation of everything that follows in diagnosis, treatment, and monitoring. It shapes the conversation with your oncologist, determines which treatments are being considered and why, and guides the imaging schedule that will track how the disease responds to therapy. Patients who understand the specific type and subtype of their cancer are better equipped to ask informed questions and participate meaningfully in decisions about their care.
For patients in Kuwait at any stage of lung cancer investigation, whether awaiting biopsy results, completing staging imaging, or beginning a monitoring program during treatment, Images Diagnostic Center provides CT and MRI services across three branches, with consistent imaging quality and efficient reporting that supports the clinical teams and patients involved in lung cancer care.
To arrange your CT scan, brain MRI, or any staging imaging related to a lung cancer evaluation in Kuwait, contact the Images team and they will coordinate your scan efficiently with your referring clinical team.
